Metaphylactic Effect of Mitomycin C with and without Hyaluronidase after Transurethral Resection of Bladder Cancer: Randomized Trial
- 1 March 1989
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 141 (3 Part 1) , 529-530
- https://doi.org/10.1016/s0022-5347(17)40881-0
Abstract
In a randomized trial 2 groups of 28 patients who had undergone transurethral resection of bladder tumors were treated with 20 mg. mitomycin C alone or with 200,000 units hyaluronidase to determine whether adjuvant hyaluronidase would improve tumor recurrence rates. Patient groups were comparable statistically. In the group receiving additive hyaluronidase the percentage of tumor recurrences was decreased significantly (p less than 0.05). Side effects were not increased. Thus, adjuvant hyaluronidase appears to have a role in the metaphylaxis of bladder tumors. The potential reduction of the hyaluronidase dose without loss of protective action and the role of additive hyaluronidase in the systemic treatment of metastatic urothelial tumors remain to be investigated.Keywords
This publication has 5 references indexed in Scilit:
- Hyaluronidase in der zytostatischen Therapie von HNO-TumorenLaryngo-Rhino-Otologie, 1987
- Adjuvant Intravesical Chemotherapy of Superficial Bladder Cancer with Monthly Doxorubicin or Intensive Mitomycin A Comparison of Two Consecutive SeriesEuropean Urology, 1987
- Mitomycin C Plasma Levels after Intravesical Instillation with and without HyaluronidaseJournal of Urology, 1986
- Mitomycin Instillation to Prevent Recurrence of Superficial Bladder CarcinomaEuropean Urology, 1983
- Long-term preservation of ischemic myocardium in the dog by hyaluronidase.Circulation, 1978